This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Ixabepilone and Pemetrexed/Solid Tumors

This study has been withdrawn prior to enrollment.
(Sponsor withdrew support)
Information provided by:
University of Southern California Identifier:
First received: November 4, 2009
Last updated: May 19, 2014
Last verified: May 2014

The purpose of the study is to determine the maximal tolerated dose (MTD) of Ixabepilone and Pemetrexed in advanced solid tumors and to obtain preliminary information regarding the activity of this combination.

This research study is for research participants who have confirmed metastatic or unresectable solid tumors (lung, breast, ovary, cervix, uterus, mesothelioma, and prostate) for which standard curative or palliative measures do not exist or no longer effective.

Condition Intervention Phase
Advanced Solid Tumors Drug: Ixabepilone Drug: Pemetrexed Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Clinical Trial of Ixabepilone and Pemetrexed in Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by University of Southern California:

Primary Outcome Measures:
  • To determine the maximal tolerated dose (MTD) of Ixabepilone and Pemetrexed in advanced solid tumors. [ Time Frame: weekly ]

Secondary Outcome Measures:
  • Response Rate [ Time Frame: every 42 days ]

Enrollment: 0
Arms Assigned Interventions
Experimental: Experimental
Escalating doses of Ixabepilone and Pemetrexed
Drug: Ixabepilone Drug: Pemetrexed


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • SWOG performance status of 0-2.
  • Projected life expectancy of at least 3 months.
  • Female and or male age 18 years and over.
  • Provision of informed consent prior to any study-related procedures.
  • Female patients must not be pregnant due to the potential mutagenicity. and teratogenicity of this treatment. A pregnancy test must be administered 7 days prior to administration of therapy to women of childbearing potential.
  • Negative pregnancy test for women of childbearing potential.
  • Patients must agree to use some form of contraception while on this study at initiation and for the duration of participation in the study. Sexually active males must also use a reliable and appropriate method of contraception. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
  • Patients must have recovered from acute toxicities from previous surgery, chemotherapy or radiation therapy.
  • Adequate organ function defined as:

    • ANC > 1500/mm3
    • Platelet count > 100,000 cells/mm3
    • Hemoglobin > 9.0g/dL
    • Serum creatinine < 1.5 mg/dl or creatinine clearance > 45 mL/minute
    • (calculated by Cockcroft-Gault formula.)
    • Hepatic function: Patients must have adequate liver functions: AST or ALT < 2.5 X upper limit of normal (ULN), alkaline phosphatase < 2.5 X upper limit of normal. In patients with bone metastasis and no evidence of liver metastasis and bilirubin < upper limit of normal an alkaline phosphatase < 5 ULN will be allowed
    • Serum Bilirubin < 1.5 mg/dL
  • Peripheral neuropathy grade 0-1.
  • No other concomitant therapy directed at the cancer is allowed.
  • The ability to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed.
  • The ability to take folic acid, Vitamin B12, and dexamethasone according to protocol.

Exclusion Criteria:

  • Laboratory results:

    • Serum bilirubin > 1.5 the upper limit of reference range (ULRR)
    • Serum creatinine >1.5 x ULRR or creatinine clearance < 45 mL/minute (calculated by Cockcroft-Gault formula)
  • Women who are currently pregnant or breast feeding.
  • Receipt of any investigational agents within 30 days prior to commencing study treatment.
  • Last dose of prior chemotherapy discontinued less than 4 weeks before the start of study therapy.
  • Last radiation therapy within the last 4 weeks before the start of study therapy, except palliative radiotherapy.
  • Prior radiation must not have included ≥ 30% of major bone marrow containing areas (pelvis, lumbar spine).
  • Any unresolved toxicity greater than CTC grade 1 from previous anti- cancer therapy, excluding alopecia.
  • CTC Grade 1 or greater neuropathy (motor or sensory) at study entry.
  • Hematologic function with absolute neutrophils ≤ 1500/mm3 and/or platelets < 100,000/mm 3.
  • Hepatic function with serum bilirubin greater than the upper institutional limits of normal, ALT and AST > 2.5 times the upper institutional limits of normal.
  • Presence of third space fluid which cannot be controlled by drainage.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01170871

United States, California
Los Angeles County+University of Southern California Medical Center
Los Angeles, California, United States, 90033
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Sponsors and Collaborators
University of Southern California
Principal Investigator: Agustin Garcia, MD Univrsity of Southern California
  More Information

Responsible Party: Agustin Garcia, MD, University of Southern California Identifier: NCT01170871     History of Changes
Other Study ID Numbers: 0C-08-2
Study First Received: November 4, 2009
Last Updated: May 19, 2014

Additional relevant MeSH terms:
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators processed this record on September 21, 2017